ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 1218

Social Determinants Shape Health Outcomes in Idiopathic Inflammatory Myopathies: Insights from Lived Experience of 1,252 Patients
Abstract Number: 1219

Anti-Ro52 Antibody Identifies Patients with More Severe Lung disease among Patients with Idiopathic Inflammatory Myopathy
Abstract Number: 1220

Predictors of Progressive Pulmonary Fibrosis in Idiopathic Inflammatory Myopathies : a Retrospective Study of 502 Cases
Abstract Number: 1221

Oxytocin pathway gene BST1 polymorphism rs4273468 genotype GG is negatively associated with Fibromyalgia
Abstract Number: 1222

Efficacy of Fasinumab, An Anti-Nerve Growth Factor Monoclonal Antibody, in Managing Chronic Musculoskeletal Pain: A Systematic Review and Meta-Analysis
Abstract Number: 1223

Pain and Fibromyalgia Across Autoimmune and Inflammatory Diseases in the AMP AIM Cohort
Abstract Number: 1224

Comparative Effectiveness of Duloxetine versus Pregabalin in Fibromyalgia: A Large-Scale, Real-World Study Across 300,000 Patients
Abstract Number: 1225

Association between Anxiety and Tender Swollen Joint Difference in Patients with Rheumatoid Arthritis
Abstract Number: 1226

Preliminary Findings in the Validation of the Modified Pain and Symptom Assessment Tool in Juvenile Fibromyalgia Syndrome
Abstract Number: 1227

The Composition of Circulating Immune Cells is Associated with Nociplastic Pain in Patients with Rheumatoid Arthritis
Abstract Number: 1228

Transcending barriers to pain care in rural America: a pragmatic comparative effectiveness trial of evidence-based, on-demand, digital behavioral treatments for chronic pain
Abstract Number: 1229

Extent versus impact: Sex-specific burden of chronic pain in older adults
Abstract Number: 1230

Chronic pain phenotypes in older adults: Identifying patterns of musculoskeletal pain and associated burden
Abstract Number: 1231

TNX-102 SL, Cyclobenzaprine HCl Sublingual Tablets, Demonstrates Pain Reduction and Favorable Tolerability in Patients with Fibromyalgia
Abstract Number: 1232

Does Social Support Reduce Bodily Pain among African American Women with SLE?: Findings from a Randomized Controlled Trial

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].